Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

See allHide authors and affiliations

Science  09 Oct 2015:
Vol. 350, Issue 6257, pp. 207-211
DOI: 10.1126/science.aad0095

Is cancer immunotherapy a private affair?

Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded.

Science, this issue p. 207, see also p. 158